Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Gastroenterology - 1 Dec 2003

Lok Anna S F, Lai Ching-Lung, Leung Nancy, Yao Guang-Bi, Cui Zhen-Yu, Schiff Eugene R, Dienstag Jules L, Heathcote E Jenny, Little Nancy R, Griffiths Dorothea A, Gardner Stephen D, Castiglia Mary

Abstract excerpt

BACKGROUND & AIMS: Data on the long-term safety of lamivudine are limited. The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment. METHODS: We reviewed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Mutation

Source

Identifiers

PMID: 14724824
DOI: 10.1053/j.gastro.2003.09.033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14724824-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.PMID 14724824Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.Semantic proximity Read ↗

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.Semantic proximity Read ↗

Lamivudine for patients with chronic hepatitis B and advanced liver disease.Semantic proximity Read ↗

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.Semantic proximity Read ↗

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.Semantic proximity Read ↗

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.